Cellectis Advances Allogeneic CAR-T Therapies with Promising Clinical Results
Finance

Cellectis Advances Allogeneic CAR-T Therapies with Promising Clinical Results

authorBy Nouriel Roubini
DateAug 25, 2026
Read time2 min

Cellectis S.A. (CLLS) is making notable progress in the field of allogeneic CAR-T cell therapies, with two key candidates, lasme-cel and eti-cel, showing promising results in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and B-cell non-Hodgkin lymphoma (r/r B-NHL) respectively. The company has maintained a 'Hold' rating as it continues to advance these innovative treatments through clinical trials, aiming to address critical unmet needs in cancer therapy.

Lasme-cel, designed for r/r B-ALL patients, has demonstrated a 100% overall response rate (ORR) in its phase 2 clinical trials. This exceptional outcome positions the therapy as a potential breakthrough for a patient population with limited options. The company anticipates releasing interim data from the pivotal phase 2 study in the fourth quarter of 2026, a critical milestone that could further validate its efficacy and safety profile.

Simultaneously, eti-cel, a unique dual-targeting CAR-T therapy against CD20 and CD22, is progressing in trials for heavily pretreated r/r B-NHL patients. Early data from phase 1 trials indicate an 88% ORR and a 63% complete remission (CR) rate, suggesting significant therapeutic potential. Full phase 1 data for eti-cel are also expected by the fourth quarter of 2026, offering more comprehensive insights into its performance.

From a financial perspective, Cellectis reports a cash runway that extends into the fourth quarter of 2027. However, to ensure sustained operations and further development beyond this period, the company will likely need to secure additional financing or forge strategic partnerships by early 2027. These financial considerations are integral to supporting the continued advancement of its therapeutic pipeline.

Cellectis is at the forefront of developing next-generation allogeneic CAR-T therapies, offering new hope for patients battling challenging blood cancers. The positive early clinical outcomes of lasme-cel and eti-cel underscore the potential of these treatments. The upcoming data readouts in late 2026 will be crucial in shaping the future trajectory of these therapies and the company's strategic financial planning.

More Articles
Finance
ACV Auctions: A Prime Takeover Target in a Consolidating Market
ACV Auctions (ACVA) is an online wholesale dealer-to-dealer auction platform showing solid operating results. More importantly, it's a hot topic for takeover rumors in a consolidating industry. The company boasts strong network effects, 10-15% GMV growth, and sells nearly 1 million cars annually. Its AI-driven VIPER inspection tool could be a key differentiator, making it an attractive bolt-on acquisition target in an industry moving towards fewer, larger platforms.
By Mariana MazzucatoAug 25, 2026
Finance
Bloom Energy’s Strong Revenue Growth and Strategic Partnerships Reshape Market Outlook
Bloom Energy has demonstrated remarkable revenue growth, with Q1 figures surging by 130% year-over-year and Q2 accelerating to an impressive 165.5%. The company’s 2026 revenue guidance has been revised upwards to $4.05 billion, a substantial increase from earlier projections. Key to this growth is a significant contract with Oracle, supporting up to 2.8 GW of power. Bloom Energy's competitive edge lies in offering cleaner onsite generation solutions, addressing critical concerns like permitting, emissions, and grid infrastructure costs more effectively than its rivals.
By Nouriel RoubiniAug 25, 2026
Finance
Broadcom's AI Ambitions and Market Volatility
Broadcom Inc. has seen a 28% stock price decline from its June 2026 peak, attributed to stagnant guidance, increasing competition, and the inherent risks of circular financing. Despite its strong growth in AI semiconductor revenue, which now constitutes over half of its segment revenue, concerns about off-balance sheet Special Purpose Vehicle (SPV) financing, insider selling, and elevated structural risks lead to a cautious outlook for AVGO shares.
By Nouriel RoubiniAug 25, 2026
Finance
Hawkins: A Deep Dive into a Niche Chemical Distributor's Market Position and Future Prospects
Hawkins, a specialty chemical distributor, has seen its stock price decline by approximately 30% from its recent peak, making its valuation more attractive. The company is now trading at a more reasonable ~23 times its projected earnings, with a manageable leverage of 1.3 times EBITDA, driven by continuous merger and acquisition activities. While organic growth and margin expansion have been modest, Hawkins maintains a strong market position, particularly in areas outside of water treatment.
By Lisa JingAug 25, 2026
Finance
Treasury General Account: Navigating Debt Ceilings and Market Impact
The Treasury General Account (TGA), a checking account at the Federal Reserve, offers flexibility for the Treasury's spending, but its use is constrained by debt ceiling considerations. A recent report suggests the Treasury might deploy up to $700 billion from the TGA, raising questions about its market impact compared to quantitative easing. However, such a deployment would likely be a temporary measure to reduce long-term debt supply for a few months, rather than a permanent change in reserve supply.
By Morgan HouselAug 25, 2026